跳至主要内容
临床试验/NCT06574594
NCT06574594招募中不适用

Effect of Methotrexate Discontinuation on Immunogenicity of Shingrix in Patients With Rheumatoid Arthritis

Konkuk University Medical Center1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2024年8月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
110
试验地点
1
主要终点
Cell-mediated immunity (CD4+ and CD8+ T cell against herpes zoster)

研究概览

简要总结

The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are:

Discontinuation of methotrexate after shingrix immunization increase efficacy of the vaccine in patients with RA ?

Researchers will compare humoral and cell-mediated immunity against herpes zoster in RA patients who are vaccinated by shingrix, and compare these immunity between RA patients with MTX discontinuation and MTX continuation groups.

Participants will:

Vaccinated with shingrix twice. MTX continuation group will keep taking MTX after shingrix vaccination, whereas MTX discontinuation group will stop MTX for 2 weeks after shingrix vaccination.

Visit the clinic at baseline (first shingrix vaccination), 2 months later for 2nd shingrix vaccination, then 3 & 6 months later from baseline to achieve blood sample.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • fulfill 2010 ACR/EULAR classification criteria for rheumatoid arthritis
  • age over 19 years
  • methotrexate user
  • agree for vaccination with shingrix

排除标准

  • have other form of inflammatory arthritis or autoimmune-mediated disease
  • malignancy, current infection, pregnancy

研究组 & 干预措施

MTX discontinuation

Experimental

methotrexate stop for 2 weeks after each shingrix vaccination

干预措施: Methotrexate (Drug)

MTX continuation

Active Comparator

干预措施: Methotrexate (Drug)

结局指标

主要结局

Cell-mediated immunity (CD4+ and CD8+ T cell against herpes zoster)

时间窗: baseline (before 1st vaccination), 1 months later from 2nd vaccination, 3 months later from 2nd vaccination

次要结局

  • , Humoral immunity (anti-VZV antibody, anti-gE antibody)(baseline (before 1st vaccination), 1 months later from 2nd vaccination, 3 months later from 2nd vaccination)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hong Ki Min

Assistant Professor

Konkuk University Medical Center

研究点 (1)

Loading locations...

相似试验